<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H0A72CCBC46344B94B0B2498DF72792B9" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 5158 IH: Fair Price Device Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-09-04</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 5158</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20250904">September 4, 2025</action-date><action-desc><sponsor name-id="S001221">Ms. Scholten</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act regarding the approval of combination products consisting of a generic drug and a device, and for other purposes.</official-title></form><legis-body id="H34318CF98A504E4AAFC7A9BA38B74BFE" style="OLC"> 
<section id="HFB2E9931760F48B3BDD9FBD4AA8AD582" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Fair Price Device Act</short-title></quote>.</text></section> <section id="HAF4224C5612945B9886F27E177A43DB8"><enum>2.</enum><header>Generic drugs for use with devices</header><text display-inline="no-display-inline">Section 505(j) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)</external-xref>) is amended—</text> 
<paragraph id="HBA15E13DB2F84EB085630F372E585C20"><enum>(1)</enum><text>in paragraph (2)(A)—</text> <subparagraph id="H7A16AA2067D643DC9088EF300ED16BDF"><enum>(A)</enum><text>in clause (v)—</text> 
<clause id="H1948E1B64F1245FD855FFA87C3AF773E"><enum>(i)</enum><text>by striking <quote>except for changes required because of differences</quote> and inserting <quote>except for changes required or appropriate, as determined by the Secretary, because of differences</quote>; and</text></clause> <clause id="H32E2A341859B4C218A5B176FC61EF955"><enum>(ii)</enum><text>by inserting <quote>, including changes as a result of differences that are otherwise permitted under this subsection, such as changes as a result of appropriate differences in the device for use with the new drug</quote> before the semicolon;</text></clause></subparagraph> 
<subparagraph id="H7AAAF1840B1B4574B861DCD4B0D9EF42"><enum>(B)</enum><text>in clause (vii), by striking the <quote>and</quote> at the end;</text></subparagraph> <subparagraph id="HFFE7B20BC35F4C59A133AD97AFD6BA68"><enum>(C)</enum><text>in clause (viii) by striking the period at the end and inserting <quote>; and</quote>;</text></subparagraph> 
<subparagraph id="HF0AB2AAE9CB64241938A86B12BBEF3F0"><enum>(D)</enum><text>by inserting after clause (viii) the following new clause:</text> <quoted-block style="OLC" id="HE1C008A7EBBB4F0C9F1AD699E0C240A9" display-inline="no-display-inline"> <clause id="H1A3F099DB8404B68ADC7061C9B909E51" indent="up2"><enum>(ix)</enum><text display-inline="yes-display-inline">if the listed drug referred to in clause (i) is intended for use with a device, relevant information as determined by the Secretary to support that the new drug for use with the device can be expected to have the same clinical effect and safety profile as the listed drug for use with the device when administered to patients under the conditions specified in the labeling of the drug, which information—</text> 
<subclause id="H0150494DBA28496F96DC0A1D43735527"><enum>(I)</enum><text>shall be in addition to information under clauses (i) through (viii) that is relevant, as determined by the Secretary, to the evaluation of the new drug for use with the device and the device proposed for use with the new drug; and</text></subclause> <subclause id="H53781382538A4CC2BF36091754625593"><enum>(II)</enum><text>may include—</text> 
<item id="H1398C01190684AF2AE9A389EF19AA933"><enum>(aa)</enum><text>information (comparative and non-comparative) regarding the device and its performance, including information about the compatibility of the new drug with the device and information regarding the delivery of the new drug when used with the device;</text></item> <item id="HFCD52B519EB1487182E3218C16E0B974"><enum>(bb)</enum><text>comparative analyses of the new drug for use with the device and the listed drug for use with its device, including information identifying any differences between the user interface of the new drug and listed drug; information identifying any differences between the user interface of the device proposed for use with the new drug and the device used with the listed drug; and information to show that, despite any such differences, the new drug when used with the device can be expected to have the same clinical effect and safety profile as the listed drug when used with the device when administered to patients under the conditions specified in the labeling of the drug; and</text></item> 
<item id="H6042608EDB044096A8E1A8DD6507736A"><enum>(cc)</enum><text>comparative and non-comparative human factors studies.</text></item></subclause></clause><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph> <subparagraph id="H801656B4C3FC458288056F35FB3A1C46" commented="no"><enum>(E)</enum><text display-inline="yes-display-inline">in the matter following clause (ix), as inserted by subparagraph (D), by striking <quote>through (viii)</quote> and inserting <quote>through (ix)</quote>; and</text></subparagraph></paragraph> 
<paragraph id="HA406D8ACA76C49E39AA1C07C6C380AA5"><enum>(2)</enum><text>in paragraph (4)—</text> <subparagraph id="H8697EF20ECB4461AA623BD037D17813A"><enum>(A)</enum><text>in subparagraph (G)—</text> 
<clause id="H1FC732B0E1E74AFB94ED621D2FB6997B"><enum>(i)</enum><text display-inline="yes-display-inline">by striking <quote>except for changes required because of differences</quote> and inserting <quote>except for changes required or appropriate, as determined by the Secretary, because of differences</quote>; and</text></clause> <clause id="H102885E973BC442197DAB108C6449403"><enum>(ii)</enum><text display-inline="yes-display-inline">by inserting <quote>, including changes as a result of differences that are otherwise permitted under this subsection, such as changes as a result of appropriate differences in the device for use with the new drug</quote> before the semicolon;</text></clause></subparagraph> 
<subparagraph id="HEDDDD8B852814CE19AAD9C5DA6DDA1C0"><enum>(B)</enum><text>by redesignating subparagraphs (J) through (K) as subparagraphs (K) through (L); and</text></subparagraph> <subparagraph id="H590212AEE76F4D919D8637D77983F58A"><enum>(C)</enum><text>by inserting after subparagraph (I) the following:</text> 
<quoted-block id="HAF98D36B3D334CC2906E7DCD8AD8B369" style="OLC"> 
<subparagraph id="HC629DDF3796D49FE9A6E15D6483A0DB6" indent="up1"><enum>(J)</enum><text>if the listed drug is intended for use with a device, information submitted in the application is insufficient to show that the new drug for use with the device can be expected to have the same clinical effect and safety profile as the listed drug for use with the device when administered to patients under the conditions specified in the labeling of the drug;</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph></section> </legis-body></bill>

